Macroautophagy and metabolomic machinery as a prospective Therapeutic Target in Endometrial hyperplasia: ERDj-3/HSP-70/C-fos/mTOR signaling pathways

Endometrial cancer (EC) is the fourth most frequent gynecological cancer and a highly abundant type of uterine cancer. There is an increase in the incidence and mortality of uterine cancers in the past few decades. A comprehensive systematic study to provide an overview on the relationship between macroautophagy, metabolomics and the risk of oestradiol valerate (OV) induced endometrial cancer was conducted correlated with the use of liposomal loaded resevetrol as an innovate drug delivery system. This article explores how metabolomic technology can offer valuable insights into autophagy molecular aspects in EC by identifying new possible metabolites that have the potential to improve the accuracy of diagnosis, prognosis, and monitoring the disease. Metabolomics approach, included orthogonal partial least squares discriminant analysis (OPLS-DA), thus revolutionizing the management of endometrial cancer and correlated it to autophagy represented in endometrial cancers, via highlighting the role of mTOR/ERDj-4/HSP-70/C-fos/PTEN/ p53 signaling pathways that trigger or inhibit the process and consequently represent a potential molecular targets in further therapeutic approaches.